Here, we developed a novel human NK cell immunotherapy targeted to DR5 (TRAILv-KHYG-1) and tested its cytotoxicity against human ovarian cancer cell lines, OVCAR-3 and SKOV-3. This evidence concerns the gene TNFRSF10B and ovarian carcinoma.